GSK and Genmab's Arzerra similar to Rituxan in RA study
This article was originally published in Scrip
Executive Summary
Preliminary results have shown that GlaxoSmithKline and Genmab's intravenous monoclonal antibody Arzerra (ofatumumab) has met the primary endpoint in its first Phase III study in rheumatoid arthritis, yielding similar results to those of Roche's anti-CD20 Rituxan (rituximab),.